The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2002 |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://revista.spmi.pt/index.php/rpmi/article/view/1852 |
Resumo: | The reduction of cholesterol, mainly with statins,achieves one of the most important benefits incardiovascular disease prevention. In Portugal, largestudies with hypolipidaemic drugs are scarce.Therefore we considered it important to conduct astudy to evaluate the efficacy and tolerability ofatorvastatin (10 and 20 mg/day) in Portuguesedyslipidaemic patients. In 16 centres, 208 ambulatorypatients, 18-70 years old, were selected and classifiedaccording to the levels of risk defined by theguidelines of the European Atherosclerosis Societyvalid at the study time. Of the 191 who startedmedication, three abandoned treatment because ofadverse events.There were highly significant differences in lipidvalues between visit V2 (basal) and V3 (one monthafter 10 mg/day of atorvastatin). Total cholesterolwas reduced by 25.2%, LDL cholesterol by 32.2%,and triglycerides by 23.3% (p<0.001). In 17% of thepatients it was necessary to double the dose ofatorvastatin, in order to try to achieve the cholesterolgoals of the respective cardiovascular risk level, andcomparing to V3 levels, total cholesterol decreasedmore 10.0% and the LDL cholesterol more 13.3%.With the 10 mg dose, HDL cholesterol increased by35% (p=0.013) in patients with a basal level under35 mg/dl (n=14), and by 15% (p<0.001) in all patientswith a basal level under 40 mg/dl (n=37).This study, in Portuguese dyslipidaemic patients,confirmed the excellent efficacy and tolerability ofatorvastatin in decreasing LDL cholesterol levelsand in increasing low HDL cholesterol levels. |
id |
RCAP_bcaa22fc23768f8c6d9729229ff7616d |
---|---|
oai_identifier_str |
oai:oai.revista.spmi.pt:article/1852 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation studyEstudo aberto de avaliação da eficácia e tolerância da atorvastatina na correcção do perfil lipídicoAtorvastatinaeficáciacolesterolHDLAtorvastatineficacycholesterolHDLThe reduction of cholesterol, mainly with statins,achieves one of the most important benefits incardiovascular disease prevention. In Portugal, largestudies with hypolipidaemic drugs are scarce.Therefore we considered it important to conduct astudy to evaluate the efficacy and tolerability ofatorvastatin (10 and 20 mg/day) in Portuguesedyslipidaemic patients. In 16 centres, 208 ambulatorypatients, 18-70 years old, were selected and classifiedaccording to the levels of risk defined by theguidelines of the European Atherosclerosis Societyvalid at the study time. Of the 191 who startedmedication, three abandoned treatment because ofadverse events.There were highly significant differences in lipidvalues between visit V2 (basal) and V3 (one monthafter 10 mg/day of atorvastatin). Total cholesterolwas reduced by 25.2%, LDL cholesterol by 32.2%,and triglycerides by 23.3% (p<0.001). In 17% of thepatients it was necessary to double the dose ofatorvastatin, in order to try to achieve the cholesterolgoals of the respective cardiovascular risk level, andcomparing to V3 levels, total cholesterol decreasedmore 10.0% and the LDL cholesterol more 13.3%.With the 10 mg dose, HDL cholesterol increased by35% (p=0.013) in patients with a basal level under35 mg/dl (n=14), and by 15% (p<0.001) in all patientswith a basal level under 40 mg/dl (n=37).This study, in Portuguese dyslipidaemic patients,confirmed the excellent efficacy and tolerability ofatorvastatin in decreasing LDL cholesterol levelsand in increasing low HDL cholesterol levels.A redução dos níveis elevados de colesterol,particularmente com as estatinas, representa um dosbenefícios clínicos mais importantes na prevençãoda doença cardiovascular. Em Portugal, são escassosgrandes estudos com fármacos hipolipemiantes, peloque se considerou de interesse avaliar a eficácia etolerância da atorvastatina, nas doses de 10 e 20 mg/dia, no tratamento de doentes dislipidémicosnacionais. Seleccionaram-se doentes ambulatórioscom idade compreendida entre os 18 e os 70 anos,sendo o nível de risco dos doentes classificado deacordo com as normas da Sociedade Europeia deAterosclerose vigentes na altura do desenho dopresente estudo. Dezasseis centros participaramneste ensaio aberto. Foram seleccionados 208doentes, tendo 191 iniciado a medicação do estudo;3 destes doentes abandonaram por eventos adversos.Verificou-se uma diferença amplamente significativa nos valores dos parâmetros do perfil lipídico entreas visitas V2 (basal) e V3 (final do período de ummês com 10 mg/dia de atorvastatina), observandose uma redução dos valores em 25,2%, 32,2% e23,3%, respectivamente no colesterol total, LDL etriglicerídeos (p<0,001). Em 17% dos doentes foinecessário duplicar a dose da atorvastatina de 10para 20 mg diários, com a finalidade de tentar atingiros objectivos para o respectivo nível de riscocardiovascular, tendo-se registado uma descidaadicional, relativamente ao valor de V3, de 10,0%para o colesterol total e de 13,3% para o C-LDL. Durante o tratamento com 10 mg/dia, nos doentescom C-HDL inferior a 35 mg/dl (n=14) assistiu-se aum aumento médio deste parâmetro em 35%(p=0,013), enquanto em todos os doentes com CHDL inferior a 40 mg/dl (n=37) a melhoria foi de15% (p<0,001).Este estudo, em doentes dislipidémicos nacionais,permitiu concluir pela excelente eficácia e tolerânciada atorvastatina na descida do C-LDL e na subidados valores baixos do C-HDL. Sociedade Portuguesa de Medicina Interna2002-06-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://revista.spmi.pt/index.php/rpmi/article/view/1852Internal Medicine; Vol. 9 No. 2 (2002): Abril/ Junho; 68-75Medicina Interna; Vol. 9 N.º 2 (2002): Abril/ Junho; 68-752183-99800872-671Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spmi.pt/index.php/rpmi/article/view/1852https://revista.spmi.pt/index.php/rpmi/article/view/1852/1294Silva, José Manuelinfo:eu-repo/semantics/openAccess2023-05-27T06:10:52Zoai:oai.revista.spmi.pt:article/1852Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:56:23.647886Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study Estudo aberto de avaliação da eficácia e tolerância da atorvastatina na correcção do perfil lipídico |
title |
The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study |
spellingShingle |
The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study Silva, José Manuel Atorvastatina eficácia colesterol HDL Atorvastatin eficacy cholesterol HDL |
title_short |
The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study |
title_full |
The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study |
title_fullStr |
The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study |
title_full_unstemmed |
The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study |
title_sort |
The efficacy of Atorvastatin in correcting the lipid profile - An open evaluation study |
author |
Silva, José Manuel |
author_facet |
Silva, José Manuel |
author_role |
author |
dc.contributor.author.fl_str_mv |
Silva, José Manuel |
dc.subject.por.fl_str_mv |
Atorvastatina eficácia colesterol HDL Atorvastatin eficacy cholesterol HDL |
topic |
Atorvastatina eficácia colesterol HDL Atorvastatin eficacy cholesterol HDL |
description |
The reduction of cholesterol, mainly with statins,achieves one of the most important benefits incardiovascular disease prevention. In Portugal, largestudies with hypolipidaemic drugs are scarce.Therefore we considered it important to conduct astudy to evaluate the efficacy and tolerability ofatorvastatin (10 and 20 mg/day) in Portuguesedyslipidaemic patients. In 16 centres, 208 ambulatorypatients, 18-70 years old, were selected and classifiedaccording to the levels of risk defined by theguidelines of the European Atherosclerosis Societyvalid at the study time. Of the 191 who startedmedication, three abandoned treatment because ofadverse events.There were highly significant differences in lipidvalues between visit V2 (basal) and V3 (one monthafter 10 mg/day of atorvastatin). Total cholesterolwas reduced by 25.2%, LDL cholesterol by 32.2%,and triglycerides by 23.3% (p<0.001). In 17% of thepatients it was necessary to double the dose ofatorvastatin, in order to try to achieve the cholesterolgoals of the respective cardiovascular risk level, andcomparing to V3 levels, total cholesterol decreasedmore 10.0% and the LDL cholesterol more 13.3%.With the 10 mg dose, HDL cholesterol increased by35% (p=0.013) in patients with a basal level under35 mg/dl (n=14), and by 15% (p<0.001) in all patientswith a basal level under 40 mg/dl (n=37).This study, in Portuguese dyslipidaemic patients,confirmed the excellent efficacy and tolerability ofatorvastatin in decreasing LDL cholesterol levelsand in increasing low HDL cholesterol levels. |
publishDate |
2002 |
dc.date.none.fl_str_mv |
2002-06-28 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://revista.spmi.pt/index.php/rpmi/article/view/1852 |
url |
https://revista.spmi.pt/index.php/rpmi/article/view/1852 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revista.spmi.pt/index.php/rpmi/article/view/1852 https://revista.spmi.pt/index.php/rpmi/article/view/1852/1294 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Medicina Interna |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Medicina Interna |
dc.source.none.fl_str_mv |
Internal Medicine; Vol. 9 No. 2 (2002): Abril/ Junho; 68-75 Medicina Interna; Vol. 9 N.º 2 (2002): Abril/ Junho; 68-75 2183-9980 0872-671X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131638922215424 |